Risk of death cut by 97% after two doses of Pfizer vaccine


wo doses of the Pfizer Covid vaccine cuts the risk of death from the virus by 97 per cent, the latest data showed.

And a single dose of the AstraZeneca vaccine reduces the risk by approximately 80 per cent.

Health Secretary Matt Hancock described the news as “life-changing” for people across the country as he urged everyone to take up their offer of a jab.

The latest data shows for the first time protection against mortality from the AstraZeneca vaccine and the additional protection provided by two doses of the Pfizer vaccine.

For its analysis, PHE said it looked at the number of new symptomatic PCR positive cases between December and April, and those who died within 28 days of their positive test and compared them according to vaccination status.

Results shows that Covid-19 cases who had had a single dose of either the Pfizer or the AstraZeneca vaccines had similar levels of protection against mortality – at 44 per cent and 55 per cent respectively – compared with people who had not had a jab.

When combined with the protection vaccines offer against becoming a case in the first place, PHE said this is equivalent to approximately 80 per cent protection against death in people who have had a single jab.

PHE said the data shows that protection against mortality from the Pfizer vaccine is even higher – around 69 per cent – for people who had their second jab at least seven days before testing positive for the virus.

The health body said a separate report it had done showed that for people aged over 80, the risk of admission to hospital with the virus is reduced by an estimated 93 per cent after two doses of Pfizer.

Mr Hancock said: “The evidence is clear that vaccines provide significant layers of protection against this awful disease. People across the country can breathe a sigh of relief knowing that their risk of becoming seriously ill or hospitalised with the virus is significantly reduced after being vaccinated.


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.